Company Overview and News
Editas Medicine has added two big hires to its board, keeping momentum on its push to be a leader in the gene-editing niche.
2018-09-27 zacks - 2
On today’s episode of Free Lunch, Associate Stock Strategist Ryan McQueeney highlights the Fed’s latest rate hike sentiment and new revisions to GDP growth estimates. He also recaps Bed Bath & Beyond’s earnings results and touches on analyst research related to Apple.
NTLA EDIT AAPL CRSP BBBY
2018-09-21 247wallst - 4
Stocks were indicated marginally higher on Friday, but this as after the Dow Jones industrials and S&P 500 hit all-time high closes on Thursday. International markets were also higher on Friday, but many international and emerging markets are still very far away from their all-time highs. As many investors have seen lower upside from buying on market pullbacks than in prior years, they have to consider how they want to have their investments positioned for the rest of 2018 and as 2019 approaches.
WFCNP CPRT UAA FSCT DRI AMD ETN NVAX AYI.WI AAI EDIT ASUV AA WFC AYI NBEV DO ACAD UA ABRW T TRI HLIT
MENLO PARK, Calif., Sept. 19, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ADVM-022. ADVM-022 is a novel gene therapy candidate for the treatment of wet age-related macular degeneration (wAMD).
REGN EDIT ADVM
MENLO PARK, Calif., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, today announced the company will be participating in the upcoming Cantor Global Healthcare Conference in New York, NY.
REGN EDIT ADVM
2018-09-11 biospace - 2
It was a win for the Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard University, as a federal court of appeals ruled against the University of California (UC) on CRISPR patents.
NTLA EDIT CRSP
CAMBRIDGE, Mass., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, announced today that the U.S. Court of Appeals for the Federal Circuit (CAFC) affirmed the U.S. Patent and Trademark Office (USPTO) decision that ended the U.S. patent interference between the University of California, the University of Vienna, and Emmanuelle Charpentier (collectively, UC) and the Broad Institute, Inc.
CRISPR pioneer Jennifer Doudna has set up shop in San Francisco’s Gladstone Institutes. Doudna, a UC Berkeley professor credited with the co-discovery of CRISPR-Cas9 genome editing technique, will focus on the development of new ways to implement the gene-editing technique for disease treatment.
2018-09-07 seekingalpha - 4
Halvorsen's 13F portfolio value increased from $16.61B to $17.47B. The number of positions increased from 58 to 60.
ATHTF CNC AVXS ILMN CVS CRM EDIT AMZN MELI AET AXON OLN GE TMUSP ANAB TMUS CTLR ABEO UTX LNC GOOGL CTLT JT ABUS 500180 AHBIF MSFT NTES CLR HBI ADS JD WFCNP DCPH EIDX FB CP JAZZ MYOV TMO LEN WDC MOMO NFLX PE LEN.B GOOG MPC CLF ECA CP HDFCBANK BIDU DIS WFC MIDD ECN BUD GEC EFX TDG ANTM ECA COL DWDP X PTEN V XRAY IQ MU HDB GNE ADSK ABEOW ANTX
2018-09-05 reuters - 1
(Reuters) - Shares of ProQR Therapeutics NV surged 70 percent in premarket trading on Tuesday after an interim analysis of an early-stage trial showed that its experimental treatment for a rare form of childhood blindness improved vision.
MENLO PARK, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, today announced its Investigational New Drug (IND) application is active for the planned multi-center, open-label, Phase 1, dose-escalation study of ADVM-022, a novel gene therapy candidate for the treatment of wet age-related macular degeneration (wAMD).
REGN EDIT ADVM
Cambridge, Mass.-based Editas Medicine, one of the leading CRISPR gene editing companies, is losing its chief medical officer. Gerald Cox will step down from his role at the end of the year. A search is underway to find a successor, Editas announced late Monday.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to EDIT / Editas Medicine, Inc. on message board site Silicon Investor.
as of ET